Login
$JAZZ
$239.77 -$1.78 (0.74%) Live

$JAZZ 8-K/A SEC Filings

Filed On Filing
05 Mar 2025 8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Form of Certificate of Incorporation of the Surviving Corporation

19 Jul 2021 8-K/A: Financial Statements and Exhibits

To the stockholders and the Board of Directors of GW Pharmaceuticals plc

27 Sep 2016 8-K/A: Financial Statements and Exhibits

We have audited the accompanying consolidated balance sheets of Celator Pharmaceuticals, Inc. and subsidiaries (the Company) as of December 31, 2015 and 2014, and the related consolidated statements of loss, stockholders’ equity, and cas...

01 Jun 2016 8-K/A: Regulation FD Disclosure

Acquisition of Celator Pharmaceuticals May 31, 2016 Exhibit 99.2

01 Apr 2014 8-K/A: Financial Statements and Exhibits

Consolidated Balance Sheets as of December 31, 2012 and 2013

20 Dec 2013 8-K/A: Entry into a Material Definitive Agreement

This TENDER OFFER AGREEMENT (this “Agreement”) is made and entered into as of December 19, 2013 (the “Agreement Date”) by and among Jazz Pharmaceuticals Public Limited Company, a public limited company formed under the laws of Ireland (“...

10 Aug 2012 8-K/A: Financial Statements and Exhibits

In our opinion, the accompanying consolidated balance sheets and the consolidated statements of operations, changes in redeemable convertible preferred stock and stockholders’ equity and cash flows present fairly, in all material respect...

23 Feb 2009 8-K/A: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support